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In  2008,  the  US  Preventive  Services  Task  Force 
(USPSTF) updated prostate cancer screening guidelines 
to  recommend  against  screening  for  prostate  cancer  in 
men aged 75 years or older. We describe the prevalence of 
prostate-specific antigen (PSA) testing in this population 
and identify factors that may be correlated with the use 
of this test.
Methods
Data  came  from  the  2006  Behavioral  Risk  Factor 
Surveillance  System.  We  assessed  the  status  of  PSA 
testing in the past year among 9,033 US men aged 76 or 
older who had no history of prostate cancer. We conducted 
descriptive  and  multiple  logistic  regression  analyses  to 
assess associations of PSA testing with certain sociodemo-
graphic and psychosocial factors.
Results
Overall, 60% of men aged 76 or older reported having a 
PSA test in the past year. Men who had health insurance, 
were satisfied with life, or always had emotional support 
were significantly more likely to report having a PSA test 
in the past year. However, men who had no routine health 
checkup; were divorced, widowed, or separated; or had less 
than a high school education were significantly less likely 
to report having had a PSA test.
Conclusion
PSA testing is common among men aged 75 or older 
in the United States. Certain sociodemographic and psy-
chosocial factors were associated with receipt of this test. 
This study may not only provide baseline data to evaluate 
acceptance and implementation of the USPSTF screening 
guidelines but may also help physicians and public health 
providers better understand these sociodemographic and 
psychosocial factors in this population.
Introduction
Prostate cancer is the most commonly diagnosed non-
skin cancer and the second leading cause of cancer death 
among US men (1). Men with indolent prostate cancers 
may not experience clinical symptoms during their life-
time; however, these indolent cancers can be detected by 
a prostate-specific antigen (PSA) screening test. Screening 
may facilitate curative treatment for prostate cancer but 
may  also  lead  to  overtreatment  (2,3).  Prostate  cancer 
treatments  can  cause  moderate  to  substantial  harm, 
including erectile dysfunction, urinary incontinence, bowel 
dysfunction, and death (4).
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In 2008, US Preventive Services Task Force (USPSTF) 
recommended  against  screening  for  prostate  cancer  in 
men aged 75 years or older, concluding that the potential 
harms outweighed the potential benefits (5). The use of 
the PSA test might be associated with certain sociodemo-
graphic and behavioral factors (marital status, education, 
access  to  health  care,  and  smoking  status)  and  chronic 
disease (6-9); however, few studies focused on men aged 
75 or older (10). To our knowledge, associations of PSA 
testing with psychosocial factors such as life satisfaction 
and  emotional  support  have  not  been  well  reported.  In 
this study, we describe the use of PSA testing among US 
men aged 75 or older and identify potential associations 
between PSA testing and sociodemographic, psychosocial, 
and behavioral factors, access to health care, and pres-
ence  of  chronic  diseases.  The  results  of  this  study  can 
establish baseline data to evaluate acceptance and future 
implementation of new USPSTF prostate cancer screening 
guidelines. Additionally, this study summarizes potential 
sociodemographic, psychosocial, and health factors associ-
ated with PSA testing in this population.
Methods
Data source
Data for this analysis came from the 2006 Behavioral 
Risk  Factor  Surveillance  System  (BRFSS),  an  ongoing, 
state-based, random-digit-dialed telephone survey of the 
noninstitutionalized US civilian population aged 18 years 
or older. BRFSS collects information on diseases, health-
related behaviors, preventive health practices, and access 
to health care in the United States, including information 
on prostate cancer testing every 2 years. The 2006 BRFSS 
data, which contained information on prostate cancer test-
ing, were published immediately before the release of the 
updated 2008 USPSTF screening guidelines. The median 
cooperation  rate  (the  percentage  of  eligible  respondents 
who completed the survey) of the 2006 BRFSS was 75%.
Study participants and variables
For respondents aged 40 or older, the use of a PSA test 
within the year before the survey was assessed with 2 ques-
tions, and prostate cancer status was determined with a 
third question (Appendix). In 2006, a total of 101,856 men 
aged 40 or older completed the BRFSS. Of these, 7,849 
men were excluded from analysis because of a history of 
prostate cancer or missing information on prostate cancer 
status. We further excluded men younger than 76 (n = 
84,228) and men (n = 746) who responded “don’t know/not 
sure” or “refused” or were missing data for the question on 
prostate cancer screening. The final sample for analysis 
included 9,033 men aged 76 years or older, representing 
an estimated population of 4.5 million US men.
In  this  study,  PSA  testing  in  the  past  year  was  the 
primary  outcome.  To  properly  categorize  men  who  had 
the PSA test at age 75 years or older, we used 76 years 
(at the time of interview) as the cutpoint for age because 
the survey asked whether the test occurred in the past 12 
months. We categorized age into 2 groups in this study: 
76 to 80 and 81 or older. We classified race/ethnicity as 
non-Hispanic  white,  non-Hispanic  black,  non-Hispanic 
Asian/Pacific Islander, Hispanic, and non-Hispanic other 
race.  All  respondents  who  reported  that  they  were  of 
Hispanic/Latino origin were coded as Hispanic. We desig-
nated marital status in 3 categories: married/living with 
a partner, divorced/widowed/separated, or never married. 
We classified educational status as less than a high school 
diploma, high school diploma, or more than a high school 
diploma. We defined smoking status as current smoker 
(respondents who reported having smoked at least 100 cig-
arettes during their lifetime and now smoke every day or 
some days), former smoker (respondents who had smoked 
at least 100 cigarettes during their lifetime and now do not 
smoke), or nonsmoker (respondents who have not smoked 
at least 100 cigarettes in their lifetime). We reclassified 
levels of emotional support as always (always or usually), 
sometimes,  or  rarely/none  and  reclassified  levels  of  life 
satisfaction as satisfied (very satisfied or satisfied) or dis-
satisfied (dissatisfied or very dissatisfied).
We regrouped routine checkup status into a dichotomous 
variable: had a checkup in the past year or no checkup in 
the  past  year.  Other  dichotomous  variables  included  in 
this analysis were health insurance, concern about medi-
cal cost, veteran status, and diagnosis of diabetes, heart 
attack,  coronary  heart  disease,  or  stroke.  Respondents 
who refused to answer, had a missing answer, or did not 
know the answer to a question were excluded from analy-
sis  of  the  specific  question.  Missing  responses  for  each 
variable ranged from 1% to 8%.
Statistical analyses
The  analysis  was  performed  by  using  SAS-callable VOLUME 7: NO. 4
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SUDAAN  version  9.0  (RTI  International,  Research 
Triangle Park, North Carolina) to account for the multi-
stage and disproportionate stratified-sampling design. We 
estimated the weighted percentages and the corresponding 
95% confidence intervals (CIs) of men aged 76 or older who 
reported having (or not having) had a PSA test in the year 
before  the  survey  by  sociodemographic,  behavioral,  and 
psychosocial factors and by status of health care access and 
chronic diseases. Significant differences in the distribution 
of these factors were determined by χ2 test with a P value 
<.05. We conducted a multiple logistic regression analysis 
to assess relationships between the use of PSA testing and 
selected  variables,  adjusting  for  potential  confounders. 
The full model included an outcome variable (had a PSA 
test in the past year) and 15 predicted variables: age, race, 
marital status, education, health insurance, concern about 
medical  cost,  routine  checkup,  veteran  status,  smoking 
status, emotional support, life satisfaction, diabetes, heart 
attack, coronary heart disease, and stroke. The Hosmer-
Lemeshow goodness-of-fit test indicated that this model 
was suitable (P = 0.93).
Results
Among US men aged 76 or older, 60% reported having 
had a PSA test in the past year (Table 1). The use of a PSA 
test was significantly higher 1) among men aged 76 to 80 
compared with men aged 81 or older; 2) among men mar-
ried or living with a partner compared with men divorced, 
widowed, or separated or never married; 3) among men 
with more than a high school diploma compared with men 
with a high school diploma or less; and 4) among men 
who were former smokers compared with men who were 
nonsmokers (Table 2). Similarly, having health insurance, 
having had a routine checkup in the past year, being a 
veteran, being satisfied with life, having had a stroke, and 
always having emotional support were significantly asso-
ciated with an increased use of PSA testing.
The multiple logistic regression analysis showed having 
health insurance, having had a routine checkup, and being 
satisfied  with  life  were  positively  associated  with  PSA 
testing (Table 3). Men who had quit smoking were more 
likely to report having a PSA test than were nonsmok-
ing men. Men who were divorced, widowed, or separated; 
rarely or never had emotional support; or had less than a 
high school education were less likely to report having the 
test than men who were married or living with partner, 
always had emotional support, or had more than a high 
school education, respectively. Veteran status and having 
had a stroke were no longer significantly associated with 
PSA testing after adjusting for all the selected variables 
simultaneously.
Discussion
We found that 60% (approximately 2.7 million) of US 
men aged 76 or older with no history of prostate cancer 
reported having had a PSA test in the past year. Our find-
ings  are  supported  by  several  previous  studies.  Among 
men aged 50 or older, 57% had a PSA screening test in 
2000, and the highest rate of screening (69%) was in men 
aged 70 to 79 (6). Data from the 2000 National Health 
Interview Survey (NHIS) showed that the PSA screening 
rate was 33% among men aged 75 or older, which account-
ed  for  approximately  two-thirds  of  PSA  tests  (10).  The 
remaining one-third of PSA tests was used for diagnostic 
purposes (ordered in the workup of symptoms, rather than 
screening of asymptomatic men) and was not included in 
the calculation of screening rates. We infer that the total 
PSA testing rate should be approximately 50%. In 2006, 
an  analysis  of  linked  data  from  the  US  Department  of 
Veterans Affairs and Medicare claims found that approxi-
mately  56%  of  men  aged  70  or  older  and  36%  of  men 
aged 85 or older were screened in 2003 (11). In 2009, the 
average rate of PSA testing in the past year was approxi-
mately 75% among men aged 75 or older (12). Data in this 
study came from medical chart audits of patients in 46   
community-based  family  medicine  practices  in  2  north-
eastern networks. The estimated PSA testing rate in this 
study  was  similar  to  self-reported  test  rates  generated 
from data of BRFSS and NHIS.
Our analyses showed certain sociodemographic and psy-
chosocial factors and health care access were significantly 
associated with receipt of a PSA test. To our knowledge, 
potential  factors  associated  with  PSA  testing  have  not 
been well characterized for men aged 75 or older. In 2003, 
researchers found that higher education levels and more 
physician  visits  were  significantly  associated  with  hav-
ing  a  PSA  test  (10).  We  confirmed  these  findings  with 
2006 BRFSS data. Additionally, our analyses suggested 
race/ethnicity was not associated with PSA testing. We 
also found that men who reported being satisfied with life, 
always having emotional support, being married or having 
a partner, or having health insurance were more likely VOLUME 7: NO. 4
JULY 2010
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to  report  having  a  PSA  test.  In  a  quality-of-life  study, 
higher socioeconomic status, good health, and good social 
relationships  were  consistently  associated  with  higher 
life satisfaction, and emotional support had the strongest 
association (13). Life satisfaction and emotional support 
are  potent  predictors  of  well-being,  an  integral  part  of 
health (13). People who perceived that they were in good 
health were more likely to believe that they would benefit 
from cancer screening (14). With a better understanding 
of patients’ sociodemographic and psychosocial character-
istics, physicians may be able to employ more appropriate 
and effective individualized strategies to frame discussions 
about PSA screening, such as formulating conversations 
with  patients  on  the  basis  of  their  health  behaviors  or 
incorporating spouses or partners into these discussions.
Although no major professional associations have recom-
mended PSA screening in elderly men, high prevalences 
of  PSA  screening  have  been  reported  (6-9,11,15).  PSA 
screening and subsequent biopsy and treatment can lead 
to psychological and physical harm and additional medi-
cal cost (16,17). The difficulty in estimating patients’ life 
expectancy  and  the  convenience  and  low  cost  of  PSA 
testing may contribute to the overuse of PSA tests in the 
elderly population (10,14). In addition, misaligned finan-
cial incentives for physician practices may also partially 
account for this problem; physicians with a laboratory on 
site are more likely to order a PSA test (18). Studies have 
suggested that a physician’s advice is a major determinant 
in a man’s decision to have a PSA test (19,20). The new 
USPSTF prostate cancer guidelines should prompt clini-
cians to discuss the potential implications of screening for 
prostate cancer before ordering a PSA test for men aged 
75 or older.
Our study findings are generalizable because they were 
generated from a nationwide population-based sampling 
survey. However, this study is subject to several limita-
tions. First, the BRFSS data were based on self-report and 
are thus subject to recall bias. Self-reports of screening 
behavior overestimate the extent of actual screening (6). 
However, the PSA testing rate reported in our study did 
not exceed the rate calculated from medical chart data in 
46 community-based primary care settings (12). Second, 
BRFSS questionnaires did not ask if people had symptoms 
of prostate cancer when their PSA tests were done. We 
could not distinguish between tests for screening (testing 
an asymptomatic person) and tests that help physicians 
make  diagnoses  (testing  a  symptomatic  person).  Thus, 
some of the PSA tests reported in our study could have 
been  used  to  assist  in  diagnosing  disease.  However,  a 
cohort study of more than 500,000 veterans aged 70 or 
older who had no history of prostate cancer, elevated PSA, 
or prostate cancer symptoms found a PSA screening rate 
of 56% (11). The distinction between a screening test and 
a diagnostic test can be difficult to make. Studies suggest 
that men who have lower urinary tract symptoms derived 
from benign prostatic hyperplasia — a common prostate 
disease in older men — are not at higher risk for prostate 
cancer, aside from the risk conferred by their age (21). 
Screening for prostate cancer could be defined as testing in 
men who do and do not have lower urinary tract symptoms 
(21). To be conservative, we explained our rates as the use 
of PSA test, instead of screening test. In an analysis of 
data from NHIS, 86% and 77% of the PSA tests in 1999 
were used for screening among men aged 65 to 79 and 
80 or older, respectively (22). Therefore, most men in our 
study were likely to have been asymptomatic at the time 
the PSA test was done. Finally, because of limited sample 
size, we could not examine PSA testing at state or local 
levels.  A  geographic  analysis  study  using  multiple-year 
BRFSS data is warranted.
In conclusion, the PSA test has been commonly used 
among US men aged 75 or older without prostate cancer, 
which might result in unnecessary physical and psycholog-
ical harm and economic cost in this age group. Physicians 
who have previously recommended prostate cancer screen-
ing for elderly patients should consider the new USPSTF 
screening  recommendation.  Our  study  may  help  physi-
cians and public health professionals better understand 
the  sociodemographic  and  psychosocial  backgrounds  of 
these  men  and  lay  groundwork  to  evaluate  acceptance 
and future implementation of the new USPSTF screening 
guidelines. Future studies to examine the possible change 
in PSA test use in this population may provide insight into 
the acceptability of discontinuing PSA testing in men aged 
75 or older.
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Tables
Table 1. PSA Testing Among Men Aged 76 Years or Older With No History of Prostate Cancer, BRFSS, 2006
PSA Test
%a
All Men (N = 9,033)
Age, y
76-80 (n = 4,858) ≥81 (n = 4,175)
In the past year 60 6 6
1-2 Years ago 11 12 10
2- Years ago 4 4 4
- Years ago   4
≥5 Years ago 4 2 
Never 18 16 21
 
Abbreviations: PSA, prostate-specific antigen; BRFSS, Behavioral Risk Factor Surveillance System. 
a Percentage population estimates adjusted for BRFSS sampling design.
Table 2. PSA Testing in the Past Year Among Men Aged 76 Years or Older With No History of Prostate Cancer, BRFSS, 2006
Characteristic No. of Mena % With PSA Test in Past Yearb P Value
Age, y
76-80 4,88 6 Reference
≥81 4,17 6 <.001
Race/ethnicity
Non-Hispanic white 7,817 61 Reference
Non-Hispanic black 7 4 .18
Non-Hispanic Asian or Pacific Islander 109 4 .1
Hispanic 4 6 .80
Non-Hispanic other 241 48 .42
Education
More than a high school diploma 4,12 64 Reference
High school diploma 2,784 8 .01
Less than a high school diploma 1,70 2 <.001
Marital status
Married or living with a partner ,10 64 Reference
Divorced/widowed/separated ,2 2 <.001
Never married 8 49 .004
Health insurance
No 21 4 Reference
Yes 8,779 61 <.001
 
Abbreviations: PSA, prostate-specific antigen; BRFSS, Behavioral Risk Factor Surveillance System. 
a Number may differ from total because of “don’t know,” refused, or missing responses. 
b Percentage population estimates adjusted for BRFSS sampling design.
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Characteristic No. of Mena % With PSA Test in Past Yearb P Value
Medical cost concern
No 8,668 60 Reference
Yes 22 7 .
Routine checkup in the past year
No 1,274  Reference
Yes 7,64 64 <.001
Veteran
No 2,17 6 Reference
Yes 6,847 62 .02
Smoking status
Nonsmoker ,17 7 Reference
Current smoker 497 7 .96
Former smoker ,0 62 .02
Life satisfaction
Dissatisfied 26 41 Reference
Satisfied 8,09 61 <.001
Emotional support
Always ,748 6 Reference
Sometimes 810  .01
Rarely/none 1,802 2 <.001
Ever had diabetes
No 7,271 60 Reference
Yes 1,749 9 .6
Ever had heart attack
No 6,878 61 Reference
Yes 2,07 9 .
Ever had coronary heart disease
No 6,922 9 Reference
Yes 1,864 6 .02
Ever had stroke
No 7,98 61 Reference
Yes 1,042  .04
 
Abbreviations: PSA, prostate-specific antigen; BRFSS, Behavioral Risk Factor Surveillance System. 
a Number may differ from total because of “don’t know,” refused, or missing responses. 
b Percentage population estimates adjusted for BRFSS sampling design.
Table 2. (continued) PSA Testing in the Past Year Among Men Aged 76 Years or Older With No History of Prostate Cancer, 
BRFSS, 2006VOLUME 7: NO. 4
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Non-Hispanic white 1.00 [Reference]
Non-Hispanic black 0.92 (0.60-1.4)
Non-Hispanic Asian or Pacific Islander 0.4 (0.14-1.27)
Hispanic 1.28 (0.78-2.10)
Non-Hispanic other 0.61 (0.6-1.0)
Education
More than a high school diploma 1.00 [Reference]
High school diploma 0.8 (0.71-1.02)
Less than a high school diploma 0.70 (0.-0.90)a
Marital status
Married or living together 1.00 [Reference]
Divorced/widowed/separated 0.71 (0.60-0.84)a







Routine checkup in the past year
No 1.00 [Reference]
Yes .7 (2.89-4.82)a






Current smoker 1.09 (0.70-1.69)











Ever had heart attack
No 1.00 [Reference]
Yes 0.8 (0.70-1.06)






Table 3. Associations Between PSA Testing and Various Characteristics Among Men Aged 76 Years or Older With No History 
of Prostate Cancer, BRFSS, 2006
Abbreviations: PSA, prostate-specific antigen; BRFSS, Behavioral Risk Factor Surveillance System; OR, odds ratio; CI, confidence interval. 
a Significant at P < .0.VOLUME 7: NO. 4
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Appendix: Behavioral Risk Factor 
Surveillance System Telephone Survey 
Questions Assessing Use of Prostate-
Specific Antigen Test and Diagnosis of 
Prostate Cancer Among US Men Aged 76 
Years or Older
1. A prostate-specific antigen test, also called a PSA test, is a blood test 
used to check men for prostate cancer. Have you ever had a PSA test?
• Yes
• No
• Do not know/not sure
• Refused
2. How long has it been since you had your last PSA test?
• Anytime less than 12 months ago
• One year but less than 2 years
• Two years but less than  years
• Three years but less than  years
• Five or more than  years
. Have you ever been told by a doctor, nurse, or other health professional 
that you had prostate cancer?
• Yes
• No
• Do not know/not sure
• Refused